JP2024539946A - プロリルヒドロキシラーゼドメイン含有タンパク質（ｐｈｄ）阻害剤およびその使用方法 - Google Patents
プロリルヒドロキシラーゼドメイン含有タンパク質（ｐｈｄ）阻害剤およびその使用方法 Download PDFInfo
- Publication number
- JP2024539946A JP2024539946A JP2024524568A JP2024524568A JP2024539946A JP 2024539946 A JP2024539946 A JP 2024539946A JP 2024524568 A JP2024524568 A JP 2024524568A JP 2024524568 A JP2024524568 A JP 2024524568A JP 2024539946 A JP2024539946 A JP 2024539946A
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- pharma
- stereoisomer
- acceptable salt
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
- C07F9/6581—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms
- C07F9/6584—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms having one phosphorus atom as ring hetero atom
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2021127023 | 2021-10-28 | ||
| CNPCT/CN2021/127023 | 2021-10-28 | ||
| CN2022112270 | 2022-08-12 | ||
| CNPCT/CN2022/112270 | 2022-08-12 | ||
| PCT/CN2022/128293 WO2023072257A1 (en) | 2021-10-28 | 2022-10-28 | Prolyl hydroxylase domain-containing protein (phd) inhibitors and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024539946A true JP2024539946A (ja) | 2024-10-31 |
| JP2024539946A5 JP2024539946A5 (https=) | 2025-10-22 |
Family
ID=86159087
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024524568A Pending JP2024539946A (ja) | 2021-10-28 | 2022-10-28 | プロリルヒドロキシラーゼドメイン含有タンパク質（ｐｈｄ）阻害剤およびその使用方法 |
| JP2024524567A Pending JP2024541910A (ja) | 2021-10-28 | 2022-10-28 | プロリルヒドロキシラーゼドメイン含有タンパク質（ｐｈｄ）阻害剤およびその使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024524567A Pending JP2024541910A (ja) | 2021-10-28 | 2022-10-28 | プロリルヒドロキシラーゼドメイン含有タンパク質（ｐｈｄ）阻害剤およびその使用方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (6) | US20250034132A1 (https=) |
| EP (2) | EP4422623A4 (https=) |
| JP (2) | JP2024539946A (https=) |
| KR (2) | KR20240095274A (https=) |
| CN (2) | CN118488838A (https=) |
| AR (3) | AR127501A1 (https=) |
| AU (1) | AU2022378858A1 (https=) |
| CA (1) | CA3235718A1 (https=) |
| IL (1) | IL312220A (https=) |
| TW (3) | TW202334158A (https=) |
| WO (3) | WO2023072246A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20240095274A (ko) | 2021-10-28 | 2024-06-25 | 인실리코 메디신 아이피 리미티드 | 프롤릴 히드록실라제 도메인-함유 단백질 (phd) 억제제 및 그의 용도 |
| GB202301059D0 (en) | 2023-01-25 | 2023-03-08 | Univ Oxford Innovation Ltd | PHD inhibitors |
| EP4702023A1 (en) * | 2023-04-28 | 2026-03-04 | Insilico Medicine IP Limited | Crystalline prolyl hydroxylase domain-containing protein (phd) inhibitor and uses thereof |
| AU2024261389A1 (en) * | 2023-04-28 | 2025-10-30 | Insilico Medicine Ip Limited | Prolyl hydroxylase domain-containing protein (phd) inhibitors, combinations and uses thereof |
| CN121057737A (zh) * | 2023-04-28 | 2025-12-02 | 英矽智能科技知识产权有限公司 | 含脯氨酰羟化酶结构域的蛋白质(phd)抑制剂结晶及其用途 |
| CN117402178B (zh) * | 2023-12-15 | 2024-03-08 | 英矽智能科技(上海)有限公司 | 作为jak抑制剂和phd抑制剂的嘧啶类化合物 |
| CN117603230B (zh) * | 2023-12-15 | 2025-03-21 | 英矽智能科技(上海)有限公司 | 作为jak抑制剂和phd抑制剂的三并环类化合物 |
| CN117756822B (zh) * | 2023-12-20 | 2025-04-18 | 英矽智能科技(上海)有限公司 | 作为jak抑制剂和phd抑制剂的嘧啶氨基类化合物 |
| CN117736227B (zh) * | 2023-12-20 | 2025-01-21 | 英矽智能科技(上海)有限公司 | 抑制jak和phd的一类化合物 |
| CN117924326B (zh) * | 2024-01-23 | 2025-01-21 | 英矽智能科技(上海)有限公司 | 一类抑制jak和phd的三并环类化合物 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6730682B2 (en) * | 2000-07-12 | 2004-05-04 | Pharmacia & Upjohn Company | Heterocycle carboxamides as antiviral agents |
| AU2003262946A1 (en) * | 2002-08-30 | 2004-03-19 | Pharmacia And Upjohn Company | Method of preventing or treating atherosclerosis or restenosis |
| US8614204B2 (en) | 2003-06-06 | 2013-12-24 | Fibrogen, Inc. | Enhanced erythropoiesis and iron metabolism |
| GB0505621D0 (en) * | 2005-03-18 | 2005-04-27 | Glaxo Group Ltd | Novel compounds |
| US8962530B2 (en) | 2007-06-27 | 2015-02-24 | Regents Of The University Of Colorado | Inflammatory bowel disease therapies |
| KR20100045480A (ko) * | 2007-08-10 | 2010-05-03 | 크리스탈지노믹스(주) | 피리딘 유도체 및 이들의 사용방법 |
| EP2536709A4 (en) | 2010-02-17 | 2013-11-27 | Univ Cornell | PROLYL HYDROXYLASE HEMMER AND USE METHOD THEREFOR |
| WO2013134660A1 (en) * | 2012-03-09 | 2013-09-12 | Fibrogen, Inc. | 4 -hydroxy- isoquinoline compounds as hif hydroxylase inhibitors |
| GB201504565D0 (en) | 2015-03-18 | 2015-05-06 | Takeda Pharmaceutical | Novel compounds |
| CN106146490B (zh) | 2015-03-27 | 2018-10-23 | 沈阳三生制药有限责任公司 | 被芳氧基或杂芳氧基取代的5-羟基-1,7-萘啶化合物、其制备方法及其制药用途 |
| CN106146491B (zh) * | 2015-03-27 | 2017-12-12 | 沈阳三生制药有限责任公司 | 被芳基或杂芳基取代的5‑羟基‑1,7‑萘啶化合物、其制备方法及其制药用途 |
| CN108341777A (zh) | 2017-01-23 | 2018-07-31 | 四川科伦博泰生物医药股份有限公司 | 异喹啉酮类化合物及其应用 |
| WO2018218042A1 (en) * | 2017-05-25 | 2018-11-29 | Enanta Pharmaceuticals, Inc. | Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof |
| TW201920108A (zh) * | 2017-09-25 | 2019-06-01 | 日商武田藥品工業有限公司 | N-(氰基取代之苄基或吡啶基甲基)-3-羥基吡啶醯胺衍生物 |
| AU2018340475B2 (en) * | 2017-09-28 | 2023-01-19 | Transthera Sciences (Nanjing), Inc. | PDE9 inhibitor and use thereof |
| CN110878096A (zh) | 2018-09-05 | 2020-03-13 | 石药集团中奇制药技术（石家庄）有限公司 | 一种1,7-萘啶类衍生物及其制备方法和用途 |
| CN112979541B (zh) | 2019-12-17 | 2022-11-11 | 浙江大学 | 一种基于n-(3-羟基吡啶-2-羰基)甘氨酸的抗肿瘤药物增敏剂及其应用 |
| WO2021163344A1 (en) * | 2020-02-12 | 2021-08-19 | Amgen Inc. | Novel prmt5 inhibitors |
| GB202004960D0 (en) * | 2020-04-03 | 2020-05-20 | Kinsenus Ltd | Inhibitor compounds |
| KR20240095274A (ko) | 2021-10-28 | 2024-06-25 | 인실리코 메디신 아이피 리미티드 | 프롤릴 히드록실라제 도메인-함유 단백질 (phd) 억제제 및 그의 용도 |
-
2022
- 2022-10-28 KR KR1020247017207A patent/KR20240095274A/ko active Pending
- 2022-10-28 EP EP22886115.9A patent/EP4422623A4/en active Pending
- 2022-10-28 WO PCT/CN2022/128237 patent/WO2023072246A1/en not_active Ceased
- 2022-10-28 JP JP2024524568A patent/JP2024539946A/ja active Pending
- 2022-10-28 CA CA3235718A patent/CA3235718A1/en active Pending
- 2022-10-28 AR ARP220102948A patent/AR127501A1/es unknown
- 2022-10-28 AR ARP220102935A patent/AR127488A1/es not_active Application Discontinuation
- 2022-10-28 IL IL312220A patent/IL312220A/en unknown
- 2022-10-28 US US18/704,366 patent/US20250034132A1/en active Pending
- 2022-10-28 KR KR1020247017209A patent/KR20240093899A/ko active Pending
- 2022-10-28 JP JP2024524567A patent/JP2024541910A/ja active Pending
- 2022-10-28 AR ARP220102947A patent/AR127500A1/es unknown
- 2022-10-28 TW TW111141254A patent/TW202334158A/zh unknown
- 2022-10-28 WO PCT/CN2022/128293 patent/WO2023072257A1/en not_active Ceased
- 2022-10-28 TW TW111141004A patent/TW202334134A/zh unknown
- 2022-10-28 US US18/704,371 patent/US20260015349A1/en active Pending
- 2022-10-28 CN CN202280086990.8A patent/CN118488838A/zh active Pending
- 2022-10-28 WO PCT/CN2022/128220 patent/WO2023072240A1/en not_active Ceased
- 2022-10-28 AU AU2022378858A patent/AU2022378858A1/en active Pending
- 2022-10-28 CN CN202280086996.5A patent/CN118591533A/zh active Pending
- 2022-10-28 EP EP22886132.4A patent/EP4423074A4/en active Pending
- 2022-10-28 TW TW111141238A patent/TW202332677A/zh unknown
-
2023
- 2023-02-15 US US18/110,259 patent/US11731987B2/en active Active
- 2023-02-15 US US18/110,261 patent/US11780854B2/en active Active
- 2023-06-22 US US18/339,362 patent/US12071443B2/en active Active
- 2023-08-31 US US18/240,886 patent/US12209101B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US11780854B2 (en) | 2023-10-10 |
| US20240002406A1 (en) | 2024-01-04 |
| EP4422623A4 (en) | 2025-10-29 |
| JP2024541910A (ja) | 2024-11-13 |
| AR127488A1 (es) | 2024-01-31 |
| AR127501A1 (es) | 2024-01-31 |
| AR127500A1 (es) | 2024-01-31 |
| TW202334134A (zh) | 2023-09-01 |
| US20250034132A1 (en) | 2025-01-30 |
| CN118488838A (zh) | 2024-08-13 |
| EP4422623A1 (en) | 2024-09-04 |
| US12209101B2 (en) | 2025-01-28 |
| KR20240095274A (ko) | 2024-06-25 |
| TW202334158A (zh) | 2023-09-01 |
| WO2023072257A1 (en) | 2023-05-04 |
| EP4423074A1 (en) | 2024-09-04 |
| CN118591533A (zh) | 2024-09-03 |
| US20230192688A1 (en) | 2023-06-22 |
| CA3235718A1 (en) | 2023-05-04 |
| US11731987B2 (en) | 2023-08-22 |
| WO2023072246A1 (en) | 2023-05-04 |
| US12071443B2 (en) | 2024-08-27 |
| TW202332677A (zh) | 2023-08-16 |
| US20240067661A1 (en) | 2024-02-29 |
| AU2022378858A1 (en) | 2024-05-02 |
| KR20240093899A (ko) | 2024-06-24 |
| US20230192723A1 (en) | 2023-06-22 |
| IL312220A (en) | 2024-06-01 |
| EP4423074A4 (en) | 2025-09-03 |
| WO2023072240A1 (en) | 2023-05-04 |
| US20260015349A1 (en) | 2026-01-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024539946A (ja) | プロリルヒドロキシラーゼドメイン含有タンパク質（ｐｈｄ）阻害剤およびその使用方法 | |
| EP3013797B1 (en) | Fused tricyclic amide compounds as multiple kinase inhibitors | |
| EP4289835A1 (en) | Cdk inhibitor | |
| JP7847123B2 (ja) | 化合物、組成物及び方法 | |
| EP3676251A1 (en) | N-(cyano-substituted benzyl or pyridinylmethyl)-3-hydroxypicolinamide derivatives useful as hif prolyl hydroxylase inhibitors | |
| TW202430152A (zh) | 野生型ｋｉｔ抑制劑 | |
| US20230219986A1 (en) | Novel aminopyrimidine egfr inhibitor | |
| JP7384535B2 (ja) | キナゾリン化合物並びにその調製方法、使用及び医薬組成物 | |
| CN113166077A (zh) | 抗细菌化合物 | |
| WO2017071516A1 (zh) | 一种蛋白激酶抑制剂及其制备方法和医药用途 | |
| TW202010500A (zh) | 作為a2a受體拮抗劑的吡唑並三唑並嘧啶衍生物 | |
| JP2025528794A (ja) | サイクリン依存性キナーゼ（ｃｄｋ）１２および／またはｃｄｋ１３の阻害剤、ならびにその使用 | |
| JP2025529942A (ja) | Ｅｐ３００／ｃｂｐ調整剤及びその製造方法と使用 | |
| CN104822658B (zh) | 作为多种激酶抑制剂的稠合三环酰胺类化合物 | |
| HK40114116A (zh) | 含脯氨酰羟化酶结构域的蛋白质(phd)抑制剂及其用途 | |
| CN116507608A (zh) | 化合物、组合物和方法 | |
| JP2023542789A (ja) | ピラゾール化合物並びにその調製方法及び使用 | |
| KR20160040182A (ko) | 다중 키나제억제제인 융합된 트리사이클릭 아미드 화합물 | |
| HK40036174A (en) | Pyrazolotriazolopyrimidine derivatives as a2a receptor antagonist |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240603 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20251014 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20251014 |